The high cost of doing business in Canada could eat this company alive. Canada has a small population and there will be a limited number of customers who are allowed to obtain medical marijuana. Insiders granted themselves stock options at a measly .89 cents per share while most of the retail investors paid 3 to 4 dollars per share for Tweed stock. The competition will be fierce and that will result in bidding wars to offer the cheapest medical marijuana prices. I think it will be very challenging for Tweed to turn a decent profit in this type of environment. The company might not make a net profit. If Tweed management had any sense they would upgrade the stock to the NYSE stock exchange. Buying volume is going to dry up if this remains on the TSX venture exchange and eventually turn into massive selling volume. Plus the company will soon be dumping their remaining surplus of shares on the market.
News 
Market Data 
Discover 
